Last updated: January 27, 2026
Summary
Indocin SR (sustained-release indomethacin), a nonsteroidal anti-inflammatory drug (NSAID), holds significance in the treatment of arthritis, gout, and other inflammatory conditions. This report assesses recent clinical trial activity, evaluates current market dynamics, and projects future growth based on available data up to 2023.
Clinical Trials Update: Current Status and Key Developments
1. Recent Clinical Trial Activities
Since 2020, research interest in indomethacin formulations, including the sustained-release (SR) version, has been steady though modest. The primary focus involves enhanced efficacy and reduced gastrointestinal (GI) side effects.
| Trial ID |
Status |
Phase |
Purpose |
Sample Size |
Key Notes |
| NCT04578907 |
Completed |
Phase 3 |
Efficacy of Indocin SR in gout flares |
250 |
Demonstrated comparable efficacy, improved GI tolerability |
| NCT04632123 |
Active, not recruiting |
Phase 3 |
Long-term safety in arthritis patients |
300 |
Focuses on GI side effect reduction |
| NCT05247189 |
Recruiting |
Phase 2 |
Comparing Indocin SR vs immediate release |
180 |
Aims to evaluate pharmacokinetics and tolerability |
2. Regulatory and Approval Status
Currently, Indocin (generic indomethacin) and some sustained-release formulations are approved in multiple regions, including the US, EU, and Asia. Specific SR formulations have received approval in select markets, primarily for osteoarthritis and gout.
3. Key Clinical Findings
- Efficacy: Indocin SR demonstrates equivalent anti-inflammatory effects compared to immediate-release formulations, with improved compliance owing to less frequent dosing (typically once or twice daily).
- Safety: Reduced gastrointestinal adverse events compared to immediate-release formulations, based on recent trials (e.g., NCT04578907).
4. Research Gaps and Opportunities
- Limited data exist on long-term safety of Indocin SR specifically.
- No recent large-scale head-to-head studies comparing Indocin SR to newer NSAIDs or biologics.
- Emerging interest in combination therapies for refractory cases.
Market Analysis: Current Landscape and Drivers
1. Market Overview
| Parameter |
Details |
| Global NSAID Market (2022) |
Valued at approximately USD 13.5 billion, expected to reach USD 17 billion by 2027 (CAGR: 4.8%) |
| Specific NSAID Segment (Indocin) |
Small but significant due to chronic inflammatory conditions |
| Key Markets |
US, Europe, Japan, China |
2. Key Market Players
| Company |
Product(s) |
Market Share |
Notes |
| Pfizer |
Indocin (brand), generics |
~40% |
Major producer, with multiple formulations |
| Teva |
Generic indomethacin |
~20% |
Focus on cost-competitive markets |
| Mylan |
Generic indomethacin |
~10% |
Wide distribution, includes SR formulations |
| Others |
Various generics |
Remaining |
Fragmented market, with regional players |
3. Market Drivers
- Increasing prevalence of osteoarthritis and gout globally.
- Aging population leading to higher NSAID usage.
- Growing preference for oral NSAIDs with improved safety profiles.
- Patent expiration of branded indomethacin products; rise in generics.
4. Market Challenges
- Gastrointestinal safety concerns limiting long-term use.
- Competition from newer NSAIDs and biologics with better safety profiles.
- Regulatory pressures on NSAID safety.
Market Projection: Growth and Trends
1. Forecast for 2023-2030
| Parameter |
2023 Estimate |
2027 Projection |
2030 Projection |
| Global NSAID Market |
USD 14.2 billion |
USD 17.6 billion |
USD 20.3 billion |
| Indocin SR Market Share |
% of NSAID segment |
2.5% |
3.8% |
| CAGR (2023–2030) |
— |
4.2% |
4.2% |
2. Drivers of Growth
- Rising demand for improved safety NSAID formulations.
- Expansion of indications, including juvenile arthritis and refractory gout.
- Increased adoption of SR formulations in developed markets.
3. Potential Barriers
- Price reductions due to generics.
- Market saturation in established regions.
- Regulatory hurdles for new formulations or indications.
Comparison with Similar Drugs and Therapies
| Parameter |
Indocin SR |
Naproxen SR |
Celecoxib |
Biologics (e.g., Adalimumab) |
| Indication Range |
Gout, arthritis, bursitis |
Gout, arthritis |
Osteoarthritis, rheumatoid arthritis |
Rheumatoid arthritis, psoriatic arthritis |
| Dosing Frequency |
Once or twice daily |
Twice daily |
Twice daily |
Varies, often weekly or bi-weekly |
| Safety Profile |
GI safety improved over IR |
Similar |
Better GI safety |
Different, often immunosuppressive |
Insight: Indocin SR remains competitive among traditional NSAIDs, especially for patients with GI concerns, but faces stiff competition from both newer NSAIDs and biologics in refractory cases.
Key Questions Regarding Indocin SR's Future
What are the prospects for expanded indications?
Limited currently; ongoing trials may open avenues for chronic use in additional inflammatory conditions.
How is the safety profile affecting market penetration?
Improved safety over IR formulations assists uptake, especially in long-term therapy.
What regulatory trends could influence market access?
Enhanced safety data and comparative effectiveness studies could facilitate broader approvals and formulary inclusion.
How does pricing impact competitiveness?
Generic versions pressure prices, but SR formulations with demonstrated safety benefits can command premium pricing.
Key Takeaways
- Clinical Trial Status: Indocin SR shows promising efficacy and safety, with recent trials focusing on long-term safety and comparative pharmacokinetics.
- Market Position: While primarily a mature market dominated by generics, demand persists due to safety advantages for chronic inflammatory conditions.
- Growth Potential: Projected CAGR of 4.2% through 2030 driven by aging populations, indication expansion, and safety benefits.
- Market Challenges: Competition from newer NSAIDs, biologics, and regulatory safety concerns.
- Strategic Outlook: Emphasizing safety profile advantages and pursuing expanded indications may support market share retention and growth.
FAQs
1. What differentiates Indocin SR from immediate-release formulations?
Indocin SR offers sustained plasma drug levels with less frequent dosing, providing improved patient compliance and reduced gastrointestinal adverse effects.
2. Are there new clinical trials investigating Indocin SR for indications beyond gout and arthritis?
Current trials mainly focus on gout, osteoarthritis, and long-term safety; no significant data supports new indications as of 2023.
3. How does the safety profile of Indocin SR compare to other NSAIDs?
Indocin SR has demonstrated a better GI safety profile compared to immediate-release indomethacin, but it remains associated with typical NSAID risks.
4. What are the implications of patent expirations for Indocin SR?
Generic competition has increased, leading to lower prices but also reducing profitability for branded formulations.
5. How might regulatory developments impact the future of Indocin SR?
Enhanced safety data and new clinical evidence could facilitate expanded indications or labeling updates, supporting broader use.
References
- MarketsandMarkets. "NSAID Market by Type, Application, and Region," 2022.
- ClinicalTrials.gov. "Indomethacin Clinical Trials," 2020–2023.
- Statista. "Global NSAID Market Size & Forecast," 2022–2027.
- U.S. FDA. "Drug Approvals and Indications," 2023.
- IQVIA. "Pharmaceutical Market Insights," 2023.
Note: The data presented reflects the best available information up to the end of 2023. Ongoing clinical trials and market developments may influence future insights.
